Effects of Cisapride, Buprenorphine, and Their Combination on Gastrointestinal Transit in New Zealand White Rabbits. Due to their effective analgesic properties, opioids are worthy of consideration for pain management in rabbits. However, this class of drugs causes undesirable effects including reduced gastrointestinal (GI) motility, reduced fecal output, and delays GI transit times and thus increases the risk of GI stasis. The risk of stasis discourages the use of opioids in rabbits, which could affect animal welfare. Gastroprokinetic agents such as cisapride are effective in promoting gastric emptying in many species, but whether this effect occurs in rabbits is unknown. This study assessed the efficacy of cisapride when administered as a single agent and in combination with buprenorphine
Cisapride An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM and EffectsSummary of Use during LactationCisapride was removed from the market in the United States by the U.S. Food and Drug Administration because of cardiac toxicity. Because of the low levels of cisapride in breastmilk, its use is acceptable in nursing mothers if it is required.Drug LevelsMaternal Levels. Ten women who averaged 1.2 days postpartum were given cisapride 20 mg orally every 8 hours for 4 days
Cisapride for gastric emptying in Diabetic patients: A Meta-Analysis on Its Efficacy and Safety PROSPERO International prospective register of systematic reviews Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied
Effect of orally administered cisapride, bethanechol, and erythromycin on the apparent efficiency of colostral IgG absorption in neonatal Holstein-Friesian calves. To evaluate the effect of orally administered cisapride, bethanechol, and erythromycin on the absorption of colostral IgG in dairy calves. Twenty-four healthy neonatal Holstein-Friesian calves. Calves were randomly assigned to one of the following treatments: 0.9% NaCl solution (2 mL, p.o.; negative control); erythromycin lactobionate (20 mg/kg BW, p.o.; anticipated to be a positive control); cisapride (0.5 mg/kg BW, p.o.); bethanechol chloride (0.5 mg/kg BW, p.o.). Calves were fed 3 L of pooled bovine colostrum containing acetaminophen (50 mg/kg) by suckling and oroesophageal intubation 30 minutes after each treatment was administered
Quality of life in patients with functional dyspepsia: Short- and long-term effect of Helicobacter pylori eradication with pantoprazole, amoxicillin, and clarithromycin or cisapride therapy: A prospective, parallel-group study. Quality of life (QOL) is impaired in functional dyspepsia (FD). Little is known about the effects of different therapies on the QOL profile in patients negative (HP-) with FD, or healthy (control group). The HP+ patients received pantoprazole 40 mg BID + amoxicillin 1000 mg BID + clarithromycin 500 mg BID for 7 days, followed by on-demand ranitidine (150-300 mg/d) for 1 year. The HP- patients received the prokinetic cisapride 10 mg TID for 1 month, followed by on-demand cisapride (10-20 mg/d) for 1 year. The FDDQoL questionnaire was completed by all 3
Clinical recovery of chronic intestinal pseudo-obstruction with cisapride in a complex pediatric patient. Cisapride is a gastrointestinal prokinetic that facilitates or restores motility along the entire gastrointestinal tract. It has been used successfully to treat acute and chronic intestinal pseudo-obstructions (CIPs) in adults, but there is a paucity of literature surrounding the treatment of CIP in pediatric patients and therapies for CIP are limited and their impact is often unsatisfactory. This case report presents the use of cisapride in the management of pseudo-obstruction. Treatment with cisapride substantially improved the patient's symptoms and improved feeding tolerance. It improved his prognosis remarkably and prevented the need for end-of-life care. He experienced no adverse
|PrucalopridePrucalopride is a dihydro‐benzofuran‐carboxamidederivative and novel serotonin 5‐HT4 agonist that pro-motes GI motility. Given its highly selective affinity toonly 5‐HT4, the risk of target‐unrelated side effects likecardiac toxicity is theoretically minimized when com-pared to cisapride and tegaserod.100,101Prucalopridehas been shown to be well tolerated by toilet‐trainedpediatric patients with FC
interactions * Note: Below are selected key drug interactions (not a comprehensive list). Pharmacist consultation and close follow-us is needed to avoid any significant adverse drug interactions. * Contraindicated with: * Clopidogrel (reduces anti-platelet effect) * MAO (monoamine oxidase) inhibitors * Thioridazine and mesoridazine * Pimozide * Terfenadine, astemizole and cisapride
for metoclopramide do not support its effectiveness in treating paediatric GERD [2][24]. The side effects of metoclopramide include extrapyramidal symptoms, tardive dyskinesia, diarrhea, and sedation [27]. Since 2015, Health Canada has counselled against use of metoclopramide in infants younger than 1 year of age.The efficacy of cisapride was evaluated in one Cochrane meta-analysis. No clear evidence that cisapride improves symptoms of GER in children was found [28]. Based on reports that it can prolong the QTc interval, leading to fatal cardiac arrhythmias and sudden death, cisapride has only been available in Canada through a limited access federal program since 2000 [4].Scant evidence to support the efficacy of prokinetics and accumulating evidence for their significant negative side-effects both
to diagnostic imaging.i. ii. • Rationale: Nurses in the community who have been assessed competent may use the auscultatory method as an option when there is no aspirate for existing NGT and when all the above measures (except CXR) have been exhausted to confirm placement. Patients on pro-kinetic medications (for example domperidone, metoclopramide, cisapride etc.) have faster
* or antimetic* or "anti-metic*" or antinausea* or "anti-nausea*" or C-4 antivomit* or "anti-vomit*" or Aprepitant or azasetron or batanopride or belidral or bendectin or benzquinamide or bromopride or buclizine or casopitant or chlorcyclizine or chlorphenethazine or Chlorpromazine or cinnarizine or cisapride or clebopride or Cyclizine or dazopride or debendox or Dexamethasone or Diazepam or difenidol
, limitations, side effectsand cost-effectiveness of medical interventions aimed atimproving intestinal motor function (eg, pyridostigmine andoctreotide), particularly those that require special protocols (eg,compassionate care program for cisapride).5.Expert performance of interventional endoscopic therapeuticprocedures (like dilation of strictures and assistance withenteral tube placement), including